AACR 2022

Sirpiglenastat (DRP-104), a novel broad acting glutamine antagonist, has therapeutic potential in targeting KEAP1-mutant lung cancer
Thales Papagiannakopoulos
Download

Festival of Biologics USA, World Immunotherapy 2022

Sirpiglenastat (DRP-104), a broad acting glutamine antagonist, metabolically reprograms glutamine addicted cancer Continue reading →

Dracen to work closely with FDA to advance the clinical program for the treatment of NSCLC with specific mutations

Dracen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s Continue reading →

Posters characterize MOA and consistent single agent activity in KEAP1 mutant tumors
Dracen Pharmaceuticals Inc., announced today that two posters profiling its lead glutamine antagonist, DRP-104, will be presented June 22-24 during the American Association for Cancer Research Virtual meeting. Continue reading →

Targeting KEAP1-Mutant NSCLC With Broad-Acting Glutamine Antagonist
Oncology Times (2022) 44(13):1,12

Targeting Glutamine Metabolism Enhances Tumor Specific Immunity by Modulating Suppressive Myeloid Cells
Journal of Clinical Investigation (2020) 131859

Tumor Microenvironment, Metabolism, and Immunotherapy
New England Journal of Medicine (2020) Continue reading →

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Dracen Pharmaceuticals Announces Oral Presentation at Festival of Biologics World Immunotherapy Congress 2022
March 18, 2022
PDF Version

Dracen Announces DRP-104 (sirpiglenastat) Presentation at ASCO 2021 Virtual Annual Meeting
June 3, 2021
PDF Version

Dracen Announces DRP-104 (sirpiglenastat) Presentations at Continue reading →

AACR 2022

Elucidating the role of glutamine metabolism in head & neck squamous cell carcinoma
Michael Allevato, Daniela Nachmanson, Sally Trinh, Yumi Yokoyama, Olivier Harismendy, Robert Wild, and J. Silvio Gutkind
Download

ASCO 2021

Trial in progress abstract: Phase 1 Continue reading →

November 8, 2019
Dracen Pharmaceuticals announces DRP-104 presentations at the 2019 Society of Immunotherapy of Cancer (SITC) Meeting

Dracen Announces AACR Presentation
April 12, 2018
PDF Version

Dracen Closes Financing to Advance Immunometabolism Pipeline
March 22, 2018
PDF Version

Dracen Continue reading →